Skip to main content
OpenTrials
Completed

NCT Number: NCT02966678

Incidence of Dyschromatopsia in Glaucoma

Incidence of dyschromatopsia

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Glaucoma Eye Diseases Ocular Hypertension

Age range

18 year–99 year

Sex eligibility

All sexes

Study type

Observational

About this study

Incidence of dyschromatopsia should be elevated in glaucoma compared to a healthy control population. However, the actual incidence rate is not investigated.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • diagnosis of glaucoma
  • age between 18 and 99 years old
  • best corrected visual acuity(BCVA) > 0.2 (decimal Snellen)

Exclusion criteria

  • age < 18 yo
  • BCVA < 0.2
  • known dyschromatopsia
  • known corneal disease
  • St.p. corneal surgeries
  • macula disease
  • history of medication use that can influence color vision (e.g. hydroxychloroquine)

Treatment and study plan

Color Vision Test

Procedure

Farnsworth Panel D15/Hue test plus Ishihara charts

Primary outcomes

  1. Incidence of dyschromatopsia

    Time frame: first and only study visit (day 1 of the study)

    Incidence of dyschromatopsia should be elevated in glaucoma compared to a healthy control population. However, the actual incidence rate is not investigated.

Sponsors and collaborators

Lead sponsor

University of Zurich

Other

Registry information

Important dates

Study start
2016
Primary completion
2017
Study completion
2017
First posted
Nov 17, 2016
Registry last updated
Jun 20, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.